-
公开(公告)号：US10265379B2
公开(公告)日：2019-04-23
申请号：US15262618
申请日：2016-09-12
IPC分类号： A61K38/17 , A61K31/10 , A61K45/06 , C12Q1/6883 , G01N33/68
摘要： A method for classifying patients at risk for cardiovascular disease, other chronic inflammatory diseases, cardiovascular and/or non-cardiovascular morbidity and mortality based on a risk assessment for lymphocyte activation gene 3 (LAG3) protein deficiency, and for mediating the risk using recombinant lymphocyte activation gene-3 or LAG3 mimetic as a companion therapeutic alone or in combination with a statin and/or an anti-hyperlipidemic drug. The risk assessment is two-prong, beginning with a qualitative determination whether a subject has or is predisposed to abnormal expression of inflammasomes, heightened risk for inflammation and/or to dysfunctional HDL, followed by a quantitative assay or genetic screen for a polymorphism that occurs in the coding sequence of the LAG3 gene. Given positive indication, recombinant LAG3 and/or LAG3 mimetic is used alone or in combination with the therapeutic use of a cholesterol mediating drug for treatment.
-
2.发明申请USE OF LYMPHOCYTE ACTIVATION GENE 3 (LAG-3) EXPRESSION PROFILING AS A BIOMARKER FOR ASSESSING INFLAMMASOMES, CHRONIC INFLAMMATORY DISEASES AND DYSFUNCTIONAL HDL 审中-公开使用LYMPHOCYTE激活基因3（LAG-3）表达谱作为生物标记物，用于评估炎症反应，慢性炎症性疾病和功能性HDL公开(公告)号：US20150355203A1
公开(公告)日：2015-12-10
申请号：US14689547
申请日：2015-04-17
IPC分类号： G01N33/92
CPC分类号： G01N33/92 , G01N2333/70596 , G01N2800/24 , G01N2800/2871 , G01N2800/50
摘要： A method for determining whether a subject has or is predisposed to abnormal expression of inflammasomes and/or to dysfunctional HDL suitable for use in diagnosing atherosclerosis, chronic inflammatory disease, Incident Cardiovascular Disease (ICD) and other pathologies characterized by an inflammatory response. Specifically, a protein assay that measures LAG-3 can be used as a diagnostic predictor of pathologies such as infection, inflammation, chronic inflammatory disease, and coronary artery disease. The diagnostic is combined with the therapeutic use of a remediating drug for treatment.
摘要翻译： 用于确定受试者是否具有或倾向于发生炎症反应的异常表达和/或适用于诊断动脉粥样硬化，慢性炎性疾病，事件性心血管疾病（ICD）和其它以炎症反应为特征的病理学的功能障碍HDL的方法。 具体来说，测量LAG-3的蛋白质测定法可用作诊断预测因素，如感染，炎症，慢性炎性疾病和冠状动脉疾病。 诊断结合治疗用药物治疗。
-
3.发明申请METHOD FOR PRE-SCREENING AND CORRELATION OF UNDERLYING SCARB1 GENE VARIATION TO INFERTILITY IN WOMEN AND THERAPEUTIC USE OF PROGESTATIONAL AND OTHER MEDICATIONS IN TREATMENT 审中-公开预先筛选和关联SCARB1基因变异对妇女感染和治疗中使用预防和其他药物治疗的方法公开(公告)号：US20130345187A1
公开(公告)日：2013-12-26
申请号：US13707256
申请日：2012-12-06
CPC分类号： A61K31/095 , A61K31/10 , A61K31/57 , A61K45/06 , C12Q1/6883 , C12Q2600/156 , A61K2300/00
摘要： A method of genotyping women experiencing infertility for non-physical reasons in order to identify the presence of the rs4238001 and/or rs10846744 mutation of the SCARB1 gene and, upon identifying the presence of one or both genetic mutations, administering a tailored therapeutic regimen to restore fertility by either one or a combination of 1) mediating the flux of cholesterol resulting from the mutation by therapeutic use of the cholesterol medication probucol and/or other cholesterol altering medications, and/or 2) amplifying the presence of hormone progesterone by therapeutic use of progestational and progestin medications.
摘要翻译： 为了识别SCARB1基因的rs4238001和/或rs10846744突变的存在以及鉴定存在一个或两个遗传突变的方法，对于非物理原因的经历不育症的妇女进行基因分型的方法，施用定制的治疗方案以恢复 生育力通过以下任何一种或组合：1）通过治疗性使用胆固醇药物普罗布考和/或其他胆固醇改变药物介导由突变引起的胆固醇通量，和/或2）通过治疗性使用来扩增激素孕酮的存在 孕激素和孕激素药物。
-
4.发明授权Method for pre-screening and correlation of underlying SCARB1 gene variation to infertility in women and therapeutic use of progestational and other medications in treatment 有权方法预先筛选和相关的潜在SCARB1基因变异与女性不育症和治疗用途孕激素和其他药物治疗公开(公告)号：US09334538B2
公开(公告)日：2016-05-10
申请号：US13707256
申请日：2012-12-06
CPC分类号： A61K31/095 , A61K31/10 , A61K31/57 , A61K45/06 , C12Q1/6883 , C12Q2600/156 , A61K2300/00
摘要： A method of genotyping women experiencing infertility for non-physical reasons in order to identify the presence of the rs4238001 and/or rs10846744 mutation of the SCARB1 gene and, upon identifying the presence of one or both genetic mutations, administering a tailored therapeutic regimen to restore fertility by either one or a combination of 1) mediating the flux of cholesterol resulting from the mutation by therapeutic use of the cholesterol medication probucol and/or other cholesterol altering medications, and/or 2) amplifying the presence of hormone progesterone by therapeutic use of progestational and progestin medications.
摘要翻译： 为了识别SCARB1基因的rs4238001和/或rs10846744突变的存在以及鉴定存在一个或两个遗传突变的方法，对于非物理原因的经历不孕症的妇女进行基因分型的方法，施用定制的治疗方案以恢复 生育力通过以下任何一种或组合：1）通过治疗性使用胆固醇药物普罗布考和/或其他胆固醇改变药物介导由突变引起的胆固醇通量，和/或2）通过治疗性使用来扩增激素孕酮的存在 孕激素和孕激素药物。
-
公开(公告)号：US20190365855A1
公开(公告)日：2019-12-05
申请号：US16360610
申请日：2019-03-21
IPC分类号： A61K38/17 , A61K31/10 , A61K45/06 , C12Q1/6883 , G01N33/68
摘要： A method for classifying patients at risk for cardiovascular disease, other chronic inflammatory diseases, cardiovascular and/or non-cardiovascular morbidity and mortality based on a risk assessment for lymphocyte activation gene 3 (LAG3) protein deficiency, and for mediating the risk using recombinant lymphocyte activation gene-3 or LAG-3 mimetic as a companion therapeutic alone or in combination with a statin and/or an anti-hyperlipidemic drug. The risk assessment is two-prong, beginning with a qualitative determination whether a subject has or is predisposed to abnormal expression of inflammasomes, heightened risk for inflammation and/or to dysfunctional HDL, followed by a quantitative assay or genetic screen for a polymorphism that occurs in the coding sequence of the LAG3 gene. Given positive indication, recombinant LAG3 and/or LAG3 mimetic is used alone or in combination with the therapeutic use of a cholesterol mediating drug for treatment.
-
6.发明申请METHOD FOR PRE-SCREENING AND CORRELATION OF UNDERLYING SCARB1 GENE VARIATION TO ATHEROSCLEROSIS IN WOMEN AND THERAPEUTIC USE OF PROGESTATIONAL AND OTHER MEDICATIONS IN TREATMENT 审中-公开用于预先筛选和相关性的SCARB1基因变异对妇女的ATHEROSCLEROSIS的预处理和相关性以及治疗和治疗中的预防和其他药物的治疗方法公开(公告)号：US20160324802A1
公开(公告)日：2016-11-10
申请号：US15095269
申请日：2016-04-11
IPC分类号： A61K31/095 , A61K45/06
CPC分类号： A61K31/095 , A61K31/10 , A61K31/57 , A61K45/06 , C12Q1/6883 , C12Q2600/156 , A61K2300/00
摘要： A method of genotyping women experiencing infertility for non-physical reasons in order to identify the presence of the rs4238001 and/or rs10846744 mutation of the SCARB1 gene and, upon identifying the presence of one or both genetic mutations, administering a tailored therapeutic regimen to restore fertility by either one or a combination of 1) mediating the flux of cholesterol resulting from the mutation by therapeutic use of the cholesterol medication probucol and/or other cholesterol altering medications, and/or 2) amplifying the presence of hormone progesterone by therapeutic use of progestational and progestin medications.
摘要翻译： 为了识别SCARB1基因的rs4238001和/或rs10846744突变的存在以及鉴定存在一个或两个遗传突变的方法，对于非物理原因的经历不育症的妇女进行基因分型的方法，施用定制的治疗方案以恢复 生育力通过以下任何一种或组合：1）通过治疗性使用胆固醇药物普罗布考和/或其他胆固醇改变药物介导由突变引起的胆固醇通量，和/或2）通过治疗性使用来扩增激素孕酮的存在 孕激素和孕激素药物。
-
公开(公告)号：US10751388B2
公开(公告)日：2020-08-25
申请号：US16360610
申请日：2019-03-21
IPC分类号： A61K38/17 , A61K31/10 , A61K45/06 , C12Q1/6883 , G01N33/68
摘要： A method for classifying patients at risk for cardiovascular disease, other chronic inflammatory diseases, cardiovascular and/or non-cardiovascular morbidity and mortality based on a risk assessment for lymphocyte activation gene 3 (LAG3) protein deficiency, and for mediating the risk using recombinant lymphocyte activation gene-3 or LAG-3 mimetic as a companion therapeutic alone or in combination with a statin and/or an anti-hyperlipidemic drug. The risk assessment is two-prong, beginning with a qualitative determination whether a subject has or is predisposed to abnormal expression of inflammasomes, heightened risk for inflammation and/or to dysfunctional HDL, followed by a quantitative assay or genetic screen for a polymorphism that occurs in the coding sequence of the LAG3 gene. Given positive indication, recombinant LAG3 and/or LAG3 mimetic is used alone or in combination with the therapeutic use of a cholesterol mediating drug for treatment.
-
公开(公告)号：US09995759B2
公开(公告)日：2018-06-12
申请号：US14689547
申请日：2015-04-17
IPC分类号： G01N33/92
CPC分类号： G01N33/92 , G01N2333/70596 , G01N2800/24 , G01N2800/2871 , G01N2800/50
摘要： A method for determining whether a subject has or is predisposed to abnormal expression of inflammasomes and/or to dysfunctional HDL suitable for use in diagnosing atherosclerosis, chronic inflammatory disease, Incident Cardiovascular Disease (ICD) and other pathologies characterized by an inflammatory response. Specifically, a protein assay that measures LAG-3 can be used as a diagnostic predictor of pathologies such as infection, inflammation, chronic inflammatory disease, and coronary artery disease. The diagnostic is combined with the therapeutic use of a remediating drug for treatment.
-
公开(公告)号：US20170312338A1
公开(公告)日：2017-11-02
申请号：US15262618
申请日：2016-09-12
CPC分类号： A61K38/1774 , A61K31/10 , A61K45/06 , C12Q1/6883 , C12Q2600/156 , G01N33/6872 , G01N2333/70503 , G01N2800/32
摘要： A method for classifying patients at risk for cardiovascular disease, other chronic inflammatory diseases, cardiovascular and/or non-cardiovascular morbidity and mortality based on a risk assessment for lymphocyte activation gene 3 (LAG3) protein deficiency, and for mediating the risk using recombinant lymphocyte activation gene-3 or LAG3 mimetic as a companion therapeutic alone or in combination with a statin and/or an anti-hyperlipidemic drug. The risk assessment is two-prong, beginning with a qualitative determination whether a subject has or is predisposed to abnormal expression of inflammasomes, heightened risk for inflammation and/or to dysfunctional HDL, followed by a quantitative assay or genetic screen for a polymorphism that occurs in the coding sequence of the LAG3 gene. Given positive indication, recombinant LAG3 and/or LAG3 mimetic is used alone or in combination with the therapeutic use of a cholesterol mediating drug for treatment.
-
-
-
-
-
-
-
-
搜索结果
9 条记录 (耗时 0.014 秒)
